PODD · 10-Q · 2026Q3 · Full report

Operating Income and Margins

INSULET CORP · 2026-11-04 · Importance 69 · Surprise 64 · In source text

Third-quarter operating income increased 61.3% year over year to $189.8 million, and operating margin expanded to 22.5% from 16.7%. Nine-month operating income grew 34.8% to $441.5 million, with operating margin of 18.4% versus 17.0% a year earlier. Quarterly revenue grew 19.2%, outpacing 12.7% growth in combined R&D and SG&A expenses. The nine-month $38.5 million net charge for the Omnipod medical device corrections was a material operating cost during the period.

Key facts

• Adjusted EBITDA was $233.7 million for the three months ended September 30, 2026, compared with $160.0 million in 2025. source
• Adjusted EBITDA was $615.1 million for the nine months ended September 30, 2026, compared with $451.5 million in 2025. source
• Selling, general and administrative expense was $1,012.8 million for the nine months ended September 30, 2026, up $179.2 million or 21.5% from $833.6 million in 2025. source
• Selling, general and administrative expense was $350.7 million for the three months ended September 30, 2026, up $35.5 million or 11.3% from $315.2 million in 2025. source
• SG&A increases in both periods primarily reflected higher personnel costs from increased headcount across commercial, customer experience, regulatory, quality and support functions, partly offset by lower expected incentive compensation; spending on commercial support programs and consulting services also increased. source
• For the nine months ended September 30, 2026, SG&A growth was further driven by higher depreciation and amortization associated with technology investments. source

Impact estimates